Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

Summary

The current study is designed to measure the corticosteroid-sparing effect of certolizumab pegol using a defined schedule of corticosteroid tapering in subjects with moderate to severe Crohn's disease. Subjects had to be in remission (CDAI\<=150) and receiving corticosteroids at a dose no higher than 30 mg/day prednisone or equivalent during the week prior to randomization.

Timeline

Start

2006-11

Primary completion

2009-07

Completion

2009-07

Drugs

Indications